Frontiers in Oncology,
Год журнала:
2023,
Номер
13
Опубликована: Авг. 28, 2023
Introduction
The
mesial
temporal
lobe
plays
a
distinct
role
in
epileptogenesis,
and
tumors
this
part
of
the
brain
potentially
have
specific
clinical
radiological
features.
Differentiating
high-grade
from
lower-grade
or
non-neoplastic
lesions
can
be
challenging,
preventing
decision
for
early
resection
that
critical
tumors.
Methods
A
tumor
database
was
analyzed
retrospectively
to
identify
patients
with
temporomesial
We
determined
features
(age,
sex,
symptoms
leading
presentation)
as
well
neuroradiological
(tumor
location
presence
contrast
enhancement
on
initial
magnetic
resonance
imaging
(MRI))
neuropathological
findings.
Results
identified
324
39
involved
lobe.
77%
occured
males,
presented
seizures,
regardless
type
grade.
In
50
years
older,
90%
were
male
80%
had
glioblastoma
(GBM);
there
no
GBM
younger
than
years.
50%
GBMs
lacked
enhancement.
Male
sex
significantly
associated
GBM.
both
contrast-enhancing
non-enhancing
tumors,
age
older
also
Conclusion
middle-aged
tumor,
is
most
likely
diagnosis
even
when
MRI
Prolonged
diagnostic
workup
surveillance
strategies
should
avoided
may
justified
these
patients.
Drug Development Research,
Год журнала:
2024,
Номер
85(7)
Опубликована: Ноя. 1, 2024
Glioblastoma
multiforme
(GBM)
remains
one
of
the
most
aggressive
and
lethal
forms
brain
cancer,
characterized
by
rapid
growth
resistance
to
conventional
therapies.
The
present
review
explores
latest
advancements
in
targeted
therapies
for
GBM,
emphasizing
critical
role
blood-brain
barrier
(BBB),
blood-brain-tumor
barrier,
tumor
microenvironment,
genetic
mutations
influencing
treatment
outcomes.
impact
key
hallmarks
example,
chemoresistance,
hypoxia,
presence
glioma
stem
cells
on
disease
progression
multidrug
are
discussed
detail.
major
focus
is
innovative
strategies
aimed
at
overcoming
these
challenges,
such
as
use
monoclonal
antibodies,
small-molecule
inhibitors,
novel
drug
delivery
systems
designed
enhance
penetration
across
BBB.
Additionally,
potential
immunotherapy,
specifically
immune
checkpoint
inhibitors
vaccine-based
approaches,
improve
patient
prognosis
was
explored.
Recent
clinical
trials
preclinical
studies
reviewed
provide
a
comprehensive
overview
current
landscape
future
prospects
GBM
treatment.
integration
advanced
computational
models
personalized
medicine
approaches
also
considered,
aiming
tailor
individual
profiles
better
efficacy.
Overall,
while
significant
progress
has
been
made
understanding
targeting
complex
biology
continued
research
innovation
imperative
develop
more
effective
sustainable
therapeutic
options
patients
battling
this
formidable
disease.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(19), С. 14960 - 14960
Опубликована: Окт. 6, 2023
The
mTOR
signaling
pathway
plays
a
pivotal
and
intricate
role
in
the
pathogenesis
of
glioblastoma,
driving
tumorigenesis
proliferation.
Mutations
or
deletions
PTEN
gene
constitutively
activate
by
expressing
growth
factors
EGF
PDGF,
which
their
respective
receptor
pathways
(e.g.,
EGFR
PDGFR).
convergence
pathways,
such
as
PI3K-AKT
pathway,
intensifies
effect
activity.
inhibition
has
potential
to
disrupt
diverse
oncogenic
processes
improve
patient
outcomes.
However,
complexity
signaling,
off-target
effects,
cytotoxicity,
suboptimal
pharmacokinetics,
drug
resistance
inhibitors
pose
ongoing
challenges
effectively
targeting
glioblastoma.
Identifying
innovative
treatment
strategies
address
these
is
vital
for
advancing
field
glioblastoma
therapeutics.
This
review
discusses
targets
target-specific
inhibitor
development,
optimized
delivery
system,
implementation
personalized
approaches
mitigate
complications
inhibitors.
exploration
precise
mTOR-targeted
therapies
ultimately
offers
elevated
therapeutic
outcomes
development
more
effective
combat
deadliest
form
adult
brain
cancer
transform
landscape
therapy.
Molecules,
Год журнала:
2024,
Номер
29(11), С. 2460 - 2460
Опубликована: Май 23, 2024
Glioblastoma,
the
most
aggressive
and
challenging
brain
tumor,
is
a
key
focus
in
neuro-oncology
due
to
its
rapid
growth
poor
prognosis.
The
C6
glioma
cell
line
often
used
as
glioblastoma
model
close
simulation
of
human
characteristics,
including
expansion
invasiveness.
Alongside,
herbal
medicine,
particularly
Artemisia
spp.,
gaining
attention
for
anticancer
potential,
offering
mechanisms
like
apoptosis
induction,
cycle
arrest,
inhibition
angiogenesis.
In
this
study,
we
optimized
extraction
conditions
polyphenols
from
annua
L.
vulgaris
herbs
investigated
their
effects
silico
vitro.
Molecular
docking
main
phenolic
compounds
A.
potential
target
proteins,
programmed
death
(apoptosis)
pathway
proteins
proapoptotic
Bax
(PDB
ID
6EB6),
anti-apoptotic
Bcl-2
G5M),
necroptosis
protein
7MON),
mixed
lineage
kinase
domain-like
(MLKL),
complex
with
receptor-interacting
serine/threonine-protein
3
(RIPK3),
revealed
high
probability
interactions,
highlighting
possible
influence
chlorogenic
acid
modulating
processes.
viability
rat
was
assessed
using
nuclear
fluorescent
double-staining
assay
Hoechst
33342
propidium
iodide.
extracts
have
demonstrated
activity
model,
synergistic
combined
surpassing
efficacy
any
single
compound.
Our
results
suggest
these
basis
developing
more
effective
treatments,
emphasizing
importance
further
research
into
action
therapeutic
applications.
Glioblastoma
(GB)
is
the
most
aggressive
and
prevalent
glioma
within
Central
Nervous
System.
GB
exhibit
a
dismal
5-year
survival
rate
(~6%)
due
to
unfavorable
prognosis
lack
of
viable
treatment
options.
Therefore,
novel
therapies
with
plant-derived
compounds
emerge
as
very
promising.
This
study
aims
investigate
antitumor
activity
7α-acetoxy-6β-hydroxyroyleanone
(Roy)
in
cell
lines.
Roy
was
isolated
from
Plectranthus
hadiensis
Schweinf.
its
mechanism
assessed
panel
five
lines
mimic
tumor
heterogeneity.
Metabolic
evaluated
by
Alamar
Blue®
assay,
while
death,
cycle
regulation,
mitochondrial
membrane
potential,
activated
caspase-3
were
flow
cytometry.
mRNA
levels
target
genes
measured
qPCR
protein
expression
Western
blotting.
Cell
uptake
impact
on
morphology
confocal
microscopy.
induced
G2/M
arrest,
fragmentation,
apoptosis
inhibiting
anti-apoptotic
proteins
increasing
concentration
6-9
fold
lower
than
those
temozolomide,
first-line
treatment.
demonstrated
robust
against
cells,
without
affecting
non
tumoral
cells
(microglia
astrocytes),
being
promising
natural
lead
compound
for
development
chemotherapeutic
approaches.
Cells,
Год журнала:
2024,
Номер
13(17), С. 1442 - 1442
Опубликована: Авг. 28, 2024
Overcoming
temozolomide
(TMZ)-resistance
is
a
major
challenge
in
glioblastoma
therapy.
Therefore,
identifying
the
key
molecular
player
chemo-resistance
becomes
urgent.
We
previously
reported
downregulation
of
PDCD10
primary
patients
and
its
tumor
suppressor-like
function
cells.
Here,
we
demonstrate
that
loss
causes
significant
TMZ-resistance
during
treatment
promotes
rapid
regrowth
cells
after
treatment.
knockdown
upregulated
MGMT,
enzyme
mediating
glioblastoma,
accompanied
by
increased
expression
DNA
mismatch
repair
genes,
enabled
to
evade
TMZ-induced
cell-cycle
arrest.
These
findings
were
confirmed
independent
models
overexpressing
Furthermore,
led
dedifferentiation
cells,
as
evidenced
clonogenic
growth,
upregulation
stem
cell
(GSC)
markers,
enhanced
neurosphere
formation
capacity.
GSCs
derived
from
displayed
stronger
potency,
compared
their
parental
counterparts,
indicating
PDCD10-induced
stemness
may
independently
contribute
malignancy.
data
provide
evidence
for
dual
role
suppression
controlling
both
dedifferentiation,
highlight
potential
prognostic
marker
target
combination
therapy
with
TMZ
glioblastoma.
INTERNATIONAL NEUROLOGICAL JOURNAL,
Год журнала:
2024,
Номер
20(2), С. 72 - 77
Опубликована: Май 6, 2024
Glioblastoma,
classified
as
a
grade
IV
astrocytoma
by
the
World
Health
Organization,
continues
to
be
very
aggressive
cancer
that
requires
comprehensive
strategy
comprising
surgery,
radiation,
and
chemotherapy.
Traditionally,
gross
total
resection
has
primarily
targeted
contrast-enhanced
regions
shown
on
T1-weighted
magnetic
resonance
images.
However,
current
studies
suggest
more
approach
focuses
removing
areas
around
tumor,
called
supramarginal
resection.
This
innovative
seeks
go
beyond
traditional
bounda-ries,
offering
possible
advantages
for
survival.
it
also
raises
worries
over
removal
of
brain
tissue
is
crucial
important
functions.
The
extremely
poor
prognosis
glioblastoma,
characterized
median
survival
10
months,
highlights
pressing
need
novel
approaches
treatment.
aim
study
evaluate
influence
with
margin
extends
much
contrast
enhancement
certain
glioblastoma
patients.
potential
documented
in
previous
collections
cases
are
consistent
notion
personalized
surgical
decision-making,
which
questions
prevailing
achieving
greatest
tumor
enhanced
contrast.
Nevertheless,
neurological
risks
should
thoroughly
evaluated.
objective
this
provide
significant
insights
into
improving
management
examining
careful
trade-off
between
preserving
function
specific
groups
